Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash from Investing Activities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Cash from Investing Activities for 3 consecutive years, with $87.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 68.2% to $87.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $99.5 million, a 18.89% decrease, with the full-year FY2025 number at $99.5 million, down 18.89% from a year prior.
  • Cash from Investing Activities was $87.1 million for Q4 2025 at Nuvation Bio, up from -$96.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $87.1 million in Q4 2025 to a low of -$96.6 million in Q3 2025.
  • A 3-year average of $19.3 million and a median of $33.7 million in 2023 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 618.4% in 2025; the steepest drop was 431.85% in 2025.
  • Nuvation Bio's Cash from Investing Activities stood at $33.2 million in 2023, then skyrocketed by 56.11% to $51.8 million in 2024, then soared by 68.2% to $87.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Cash from Investing Activities are $87.1 million (Q4 2025), -$96.6 million (Q3 2025), and $54.9 million (Q2 2025).